A Phase I/II, Open Label, Multicenter Study of ACY-1215 in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Ricolinostat (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Acetylon Pharmaceuticals; Celgene Corporation
- 28 Nov 2017 Planned End Date changed from 30 Oct 2017 to 30 Mar 2018.
- 28 Nov 2017 Planned primary completion date changed from 30 Oct 2017 to 30 Mar 2018.
- 12 Jun 2017 Planned End Date changed from 1 Dec 2017 to 30 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History